Sandoz Group AG (SDZNY)
35.15
+0.06
(+0.17%)
USD |
OTCM |
May 22, 16:15
Sandoz Group SG&A Expense (Quarterly): 68.78M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 68.78M |
December 31, 2023 | 95.89M |
September 30, 2023 | 171.66M |
June 30, 2023 | 144.83M |
March 31, 2023 | 64.32M |
December 31, 2022 | 193.15M |
Date | Value |
---|---|
September 30, 2022 | 176.28M |
June 30, 2022 | 128.21M |
March 31, 2022 | 73.08M |
December 31, 2021 | 113.24M |
September 30, 2021 | 116.60M |
June 30, 2021 | 84.97M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
64.32M
Minimum
Mar 2023
193.15M
Maximum
Dec 2022
119.25M
Average
114.92M
Median
SG&A Expense (Quarterly) Benchmarks
Novartis AG | 2.84B |
AC Immune SA | 5.688M |
CRISPR Therapeutics AG | 17.95M |
Addex Therapeutics Ltd | 1.922M |
NLS Pharmaceutics Ltd | -- |